Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

NCT04317066

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Nagoya University Hospital ( Site 0002) Nagoya, Aichi-ken, Japan
  • Hokkaido University Hospital ( Site 0006) Sapporo, Hokkaido, Japan
  • Kindai University Hospital ( Site 0001) Sayama, Osaka, Japan
  • National Hospital Organization Disaster Medical Center ( Site 0007) Tachikawa, Tokyo, Japan
View Trial Details
Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

NCT04676412

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Anhui Provincial Hospital ( Site 0108) Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0113) Hefei, Anhui, China
  • Peking Union Medical College Hospital ( Site 0105) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0102) Beijing, Beijing Municipality, China
View all 17 locations
View Trial Details
Completed

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

NCT03631784

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • St Joseph Heritage Healthcare ( Site 1403) Santa Rosa, California, United States
  • North Shore University Health System ( Site 1413) Evanston, Illinois, United States
  • Parkview Cancer Institute ( Site 1415) Fort Wayne, Indiana, United States
  • UMass Memorial Medical Center ( Site 1417) Worcester, Massachusetts, United States
View all 56 locations
View Trial Details
Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

NCT03631407

Conditions
Brain Diseases, Central Nervous System Diseases, Cerebellar Diseases, +19 more
Locations
  • Honor Health ( Site 0103) Scottsdale, Arizona, United States
  • California Cancer Associates for Research & Excellence ( Site 0100) Encinitas, California, United States
  • California Cancer Associates for Research & Excellence ( Site 0102) Fresno, California, United States
  • Florida Cancer Specialists (South Region) - Research Office ( Site 7001) Fort Myers, Florida, United States
View Trial Details
Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

NCT03374254

Conditions
Brain Diseases, Central Nervous System Diseases, Cerebellar Diseases, +20 more
Locations
  • City of Hope National Medical Center ( Site 0102) Duarte, California, United States
  • Anschutz Medical Campus, Anschutz Cancer Pavilion ( Site 0106) Aurora, Colorado, United States
  • Yale Cancer Center ( Site 0108) New Haven, Connecticut, United States
  • Moffitt Cancer Center ( Site 0111) Tampa, Florida, United States
View all 14 locations
View Trial Details
Completed

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, +7 more
Locations
  • Kaiser Permanente Southern California ( Site 0003) West Los Angeles, California, United States
  • The University of Chicago Medical Center ( Site 0001) Chicago, Illinois, United States
  • University of Kansas ( Site 0029) Westwood, Kansas, United States
  • University of Maryland Medical Center ( Site 0013) Baltimore, Maryland, United States
View all 189 locations
View Trial Details
Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

NCT03776136

Conditions
Advanced Melanoma, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Ironwood Cancer & Research Centers ( Site 0312) Chandler, Arizona, United States
  • John Wayne Cancer Institute ( Site 0301) Santa Monica, California, United States
  • Advocate Medical Group-Park Ridge ( Site 0313) Park Ridge, Illinois, United States
  • Southeast Nebraska Cancer Center ( Site 0316) Lincoln, Nebraska, United States
View all 23 locations
View Trial Details

Related conditions